Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 9/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 8/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25971538 | 0.87 | KDM4E (0.36) | SMN1; SMN2HSD11B1KDM4EMAPTKDM4C | |
| SCHEMBL25988291 | 0.83 | BACE1 (0.40) | HSD11B1 | |
| SCHEMBL23052957 | 0.82 | NPSR1 (0.50) | SMN1; SMN2HSD11B1CHRM2CHRM3CHRM4 | |
| SCHEMBL25971004 | 0.71 | MCOLN3 (0.38) | SMN1; SMN2HSD11B1CHRM2CHRM3CHRM4 | |
| SCHEMBL18481610 | 0.69 | CHRM2 (0.38) | CHRM2CHRM3CHRM4CHRM5CHRM1 | |
| SCHEMBL22458648 | 0.69 | CHRM2 (0.38) | CHRM2CHRM3CHRM4CHRM5CHRM1 | |
| SCHEMBL26999038 | 0.69 | CHRM2 (0.38) | CHRM2CHRM3CHRM4CHRM5CHRM1 | |
| SCHEMBL13910978 | 0.69 | CHRM2 (0.38) | CHRM2CHRM3CHRM4CHRM5CHRM1 | |
| SCHEMBL12513017 | 0.69 | CHRM2 (0.38) | CHRM2CHRM3CHRM4CHRM5CHRM1 | |
| SCHEMBL25980370 | 0.69 | APP (0.38) | HSD11B1CHRM2CHRM3CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312630-A1 | PHOSPHORAMIDITE SYNTHESIS ON-DEMAND | AARHUS UNIVERSITET (DK) | 2023-10-05 | — | — | US | disclosed |
| US-20230312630-A1 | PHOSPHORAMIDITE SYNTHESIS ON-DEMAND | AARHUS UNIVERSITET (DK) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312630-A1 | PHOSPHORAMIDITE SYNTHESIS ON-DEMAND | RNGTT, PPA1, PNP | SMN1; SMN2 1739/4885HSD11B1 4461/4885CHRM2 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.